Caroline Nebhan, MD, PhD, clinical fellow, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

During the 2021 SITC Annual Meeting, findings from a multicenter, international cohort study evaluating the efficacy and toxicity of single-agent checkpoint inhibitors in patients with cancer aged 80 years or older were presented in a virtual poster.

The efficacy analysis evaluated patients with the 3 most common tumor types represented in the study: non–small cell lung cancer (NSCLC), melanoma, and genitourinary (GU) tumors, Nebhan says. The results of the study demonstrated that the objective response rate was 32.2% in patients with NSCLC, 39.3% in patients with melanoma, and 26.2% in patients with GU tumors. The median progression-free survival was 6.7 months, 11.1 months, and 6 months, respectively. 

Ultimately, these findings demonstrated that older patients with NSCLC, melanoma, or GU tumors can derive a substantial response with single-agent checkpoint inhibitors, Nebhan concludes.

Videos

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Caroline Nebhan, MD, PhD

Articles

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer